[go: up one dir, main page]

BRPI0511581A - derivados de tetrahidroisoquinolilsulfonamidas, sua preparação e sua utilização em terapêutica - Google Patents

derivados de tetrahidroisoquinolilsulfonamidas, sua preparação e sua utilização em terapêutica

Info

Publication number
BRPI0511581A
BRPI0511581A BRPI0511581-7A BRPI0511581A BRPI0511581A BR PI0511581 A BRPI0511581 A BR PI0511581A BR PI0511581 A BRPI0511581 A BR PI0511581A BR PI0511581 A BRPI0511581 A BR PI0511581A
Authority
BR
Brazil
Prior art keywords
group
alkylidene
alkyl
optionally substituted
hydrogen atom
Prior art date
Application number
BRPI0511581-7A
Other languages
English (en)
Inventor
Juan Antonio Diaz Martin
Maria Dolores Jimenez Bargueno
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34944870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0511581(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of BRPI0511581A publication Critical patent/BRPI0511581A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

DERIVADOS DE TETRAHIDROISOQUINO-LILSULFONAMIDAS, SUA PREPARAçãO E SUA UTILIZAçãO EM TERAPêUTICA. A presente invenção refere-se a composto correspondente à fórmula (I), na qual: n pode assumir um valor de 1 a 6; -(C)n- representa um grupo -C~ 1-6~ alquilideno, eventualmente substituído por 1 a 4 substituintes; R1 representa um átomo de hidrogênio, um grupo C~ 1-6~alquila; R2 representa um átomo de hidrogênio, um grupo C~ 1-6~alquila ou C~ 3-6~cicloalquila eventualmente substituído por 1 a 4 substituintes; B representa NR3R4, R3 e R4 representam, independentemente um do outro, um grupo C~ 1-6~ alquila, um átomo de hidrogênio; ou R3 e R4 representam juntos um grupo C~ 1-6~ alquilideno, um grupo C~ 2-8~ alquenilideno, um grupo C~ 1-3~ alquilideno-O-C~ 1-3~ alquilideno, ou um grupo C~ 1-3~ alquilideno-N-(R5)-C~ 1-3~ alquilideno no qual R5 representa um átomo de hidrogênio, um grupo C~ 1-3~ alquila ou C~ 1-6~ alquilcarbonila, esses grupos C~ 1-3~ alquila e C~ 1-6~ alquilcarbonila podendo ser substituídos; ou um aminociclo, ligado por um carbono ao grupo -NR1-(C)n-, tal como aziridina, azetidina, pirrolidina, piperidina ou morfolina; os grupos R3, R4, assim como o aminociclo sendo eventualmente substituídos e átomo de nitrogênio eventualmente substituído. Aplicação em terapêutica.
BRPI0511581-7A 2004-05-25 2005-05-24 derivados de tetrahidroisoquinolilsulfonamidas, sua preparação e sua utilização em terapêutica BRPI0511581A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0405607A FR2870846B1 (fr) 2004-05-25 2004-05-25 Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique
PCT/FR2005/001279 WO2005118547A1 (fr) 2004-05-25 2005-05-24 Derives de tetrahydroisoquinolilsulfonamides, leur preparation et leur utilisation en therapeutique

Publications (1)

Publication Number Publication Date
BRPI0511581A true BRPI0511581A (pt) 2008-01-02

Family

ID=34944870

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511581-7A BRPI0511581A (pt) 2004-05-25 2005-05-24 derivados de tetrahidroisoquinolilsulfonamidas, sua preparação e sua utilização em terapêutica

Country Status (41)

Country Link
US (3) US7833999B2 (pt)
EP (1) EP1753725B1 (pt)
JP (1) JP4861979B2 (pt)
KR (1) KR101176675B1 (pt)
CN (1) CN1956962B (pt)
AR (1) AR050250A1 (pt)
AU (1) AU2005250197B2 (pt)
BR (1) BRPI0511581A (pt)
CA (1) CA2565293C (pt)
CR (1) CR8735A (pt)
CY (1) CY1114240T1 (pt)
DK (1) DK1753725T3 (pt)
DO (1) DOP2005000103A (pt)
EA (1) EA010234B1 (pt)
EC (1) ECSP067020A (pt)
ES (1) ES2407140T3 (pt)
FR (1) FR2870846B1 (pt)
GT (1) GT200500126A (pt)
HK (1) HK1106229A1 (pt)
HN (1) HN2005000239A (pt)
HR (1) HRP20130431T1 (pt)
IL (1) IL179021A (pt)
JO (1) JO2877B1 (pt)
MA (1) MA28720B1 (pt)
MX (1) MXPA06013629A (pt)
MY (1) MY148980A (pt)
NI (1) NI200600279A (pt)
NO (1) NO338104B1 (pt)
NZ (1) NZ551509A (pt)
PA (1) PA8634501A1 (pt)
PE (1) PE20060273A1 (pt)
PL (1) PL1753725T3 (pt)
PT (1) PT1753725E (pt)
SI (1) SI1753725T1 (pt)
SV (1) SV2006002126A (pt)
TN (1) TNSN06356A1 (pt)
TW (1) TWI360540B (pt)
UA (1) UA84771C2 (pt)
UY (1) UY28917A1 (pt)
WO (1) WO2005118547A1 (pt)
ZA (1) ZA200609820B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2870846B1 (fr) * 2004-05-25 2006-08-04 Sanofi Synthelabo Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique
EP1790646A1 (fr) * 2005-11-24 2007-05-30 Sanofi-Aventis Derives de Isoquinoline et Benzo[h]Isoquinoline, leur preparation et leur utilisation en thérapeutique en tant qu'antagonistes du recepteur de l'histamine H3.
PH12012501917A1 (en) 2007-11-13 2014-10-17 Taisho Pharmaceutical Co Ltd Phenylpyrazole derivatives
TW201039822A (en) 2009-02-06 2010-11-16 Taisho Pharmaceutical Co Ltd Dihydroquinolinone derivatives
RU2537847C2 (ru) 2009-06-26 2015-01-10 Санофи Новые фумаратные соли антагониста гистаминового рецептора н3
AR080375A1 (es) * 2010-03-05 2012-04-04 Sanofi Aventis Procedimiento para la preparacion de 2-(cicloheximetil)-n-{2-[(2s)-1-metilpirrolidin-2-il] etil}-1,2,3,4-tetrahidroisoquinolina- 7-sulfonamida
RU2618228C2 (ru) 2011-12-08 2017-05-03 Тайсо Фармасьютикал Ко., Лтд. Производное фенилпиррола
WO2013100054A1 (ja) 2011-12-27 2013-07-04 大正製薬株式会社 フェニルトリアゾール誘導体
EP2647377A1 (en) * 2012-04-06 2013-10-09 Sanofi Use of an h3 receptor antagonist for the treatment of alzheimer's disease
CN105764510A (zh) * 2013-09-09 2016-07-13 赛诺菲 H3受体拮抗剂与胆碱酶抑制剂组合用于阿尔茨海默氏病治疗中的用途
CN110642854A (zh) * 2019-11-20 2020-01-03 成都克莱蒙医药科技有限公司 一种稠环化合物的多晶型、其组合物、制备方法及其应用
WO2022113008A1 (en) 2020-11-27 2022-06-02 Richter Gedeon Nyrt. Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0702671A4 (en) 1993-06-09 1996-06-19 Smithkline Beecham Corp BICYCLIC FIBRINOGEN ANTAGONISTS
GB9508622D0 (en) 1995-04-28 1995-06-14 Pfizer Ltd Therapeutic agants
US6080871A (en) * 1996-02-09 2000-06-27 James Black Foundation Limited Sulfonamides and sulfamides as H3 receptor antagonists
CN1305470A (zh) 1998-04-10 2001-07-25 日本烟草产业株式会社 脒化合物
WO2000071493A2 (en) 1999-05-24 2000-11-30 Cor Therapeutics, Inc. INHIBITORS OF FACTOR Xa
JP4031363B2 (ja) 2001-01-02 2008-01-09 エフ．ホフマン−ラ ロシュ アーゲー α−１Ａ／Ｂアドレナリン作動性受容体拮抗薬としてのキナゾロン誘導体
AU2002254114A1 (en) * 2001-03-23 2002-10-08 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
US20050154230A1 (en) * 2001-12-26 2005-07-14 Bayer Healthcare Ag Urea derivatives
JP2003192660A (ja) * 2001-12-26 2003-07-09 Bayer Ag 尿素誘導体
KR100984655B1 (ko) 2002-03-08 2010-10-01 사카타 인쿠스 가부시키가이샤 처리안료, 그 용도 및 안료처리용 화합물
GB0206033D0 (en) 2002-03-14 2002-04-24 Pfizer Ltd Compounds useful in therapy
PL375513A1 (en) * 2002-08-29 2005-11-28 Boehringer Ingelheim Pharmaceuticals, Inc. 3-(sulfonamidoethyl)-indole derivatives for use as glucocorticoid mimetics in the treatment of inflammatory, allergic and proliferative diseases
CN1886393A (zh) 2003-10-08 2006-12-27 沃泰克斯药物股份有限公司 含有环烷基或吡喃基基团的atp－结合弹夹转运蛋白的调控剂
US20070099938A1 (en) 2003-10-24 2007-05-03 Ono Pharmaceutical Co., Ltd. Antistress drug and medical use thereof
FR2870846B1 (fr) * 2004-05-25 2006-08-04 Sanofi Synthelabo Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique
EP1630158A1 (en) 2004-08-18 2006-03-01 Laboratorios Del Dr. Esteve, S.A. 5-HT7 receptor antagonists
EP1630159A1 (en) 2004-08-18 2006-03-01 Laboratorios Del Dr. Esteve, S.A. 5-HT7 receptor antagonists
US20080261999A1 (en) 2005-03-04 2008-10-23 Fionna Mitchell Martin Azabicycloalkane Derivatives Useful as Nicotinic Acetylcholine Receptor Agonists
EP1790646A1 (fr) 2005-11-24 2007-05-30 Sanofi-Aventis Derives de Isoquinoline et Benzo[h]Isoquinoline, leur preparation et leur utilisation en thérapeutique en tant qu'antagonistes du recepteur de l'histamine H3.

Also Published As

Publication number Publication date
UA84771C2 (uk) 2008-11-25
ES2407140T3 (es) 2013-06-11
HK1106229A1 (en) 2008-03-07
FR2870846A1 (fr) 2005-12-02
EP1753725B1 (fr) 2013-02-27
NI200600279A (es) 2008-01-22
US20070105834A1 (en) 2007-05-10
EA010234B1 (ru) 2008-06-30
WO2005118547A1 (fr) 2005-12-15
PT1753725E (pt) 2013-05-21
SV2006002126A (es) 2006-01-13
SI1753725T1 (sl) 2013-06-28
KR101176675B1 (ko) 2012-08-23
US8273733B2 (en) 2012-09-25
PA8634501A1 (es) 2006-05-16
NZ551509A (en) 2009-12-24
NO20065918L (no) 2006-12-19
TWI360540B (en) 2012-03-21
US20110028475A1 (en) 2011-02-03
DOP2005000103A (es) 2006-02-15
CY1114240T1 (el) 2016-08-31
CA2565293C (fr) 2012-10-30
CN1956962B (zh) 2014-08-20
CA2565293A1 (fr) 2005-12-15
CN1956962A (zh) 2007-05-02
JP4861979B2 (ja) 2012-01-25
ECSP067020A (es) 2006-12-29
EP1753725A1 (fr) 2007-02-21
GT200500126A (es) 2006-02-17
US8524700B2 (en) 2013-09-03
PL1753725T3 (pl) 2013-07-31
KR20070021223A (ko) 2007-02-22
JO2877B1 (en) 2015-03-15
US20120323003A1 (en) 2012-12-20
EA200602176A1 (ru) 2007-04-27
IL179021A0 (en) 2007-03-08
TNSN06356A1 (en) 2008-02-22
AU2005250197B2 (en) 2010-09-23
ZA200609820B (en) 2008-06-25
NO338104B1 (no) 2016-08-01
AU2005250197A1 (en) 2005-12-15
JP2008500313A (ja) 2008-01-10
HRP20130431T1 (en) 2013-06-30
UY28917A1 (es) 2005-12-30
TW200609220A (en) 2006-03-16
IL179021A (en) 2012-04-30
MA28720B1 (fr) 2007-07-02
PE20060273A1 (es) 2006-04-22
CR8735A (es) 2007-08-28
DK1753725T3 (da) 2013-05-27
HN2005000239A (es) 2009-04-27
FR2870846B1 (fr) 2006-08-04
MY148980A (en) 2013-06-28
MXPA06013629A (es) 2007-03-23
US7833999B2 (en) 2010-11-16
AR050250A1 (es) 2006-10-11

Similar Documents

Publication Publication Date Title
CY1114240T1 (el) Παραγωγα σουλφοναμιδιου τετραϋδροϊσοκινολινης, η παρασκευη τους και η χρηση τους στη θεραπευτικη
AR037534A1 (es) Derivado de adamantano, su uso en la fabricacion de un medicamento para usar en terapia, composicion farmaceutica, proceso para la preparacion de dicho compuesto y dicha composicion y compuestos intermediarios
NO20054224L (no) Nye 2-pyridinkarboksamidderivater
NO20071642L (no) N-Benzensulfonylsubstituerte anilino-pyrimidinanaloger
ATE334654T1 (de) Vor uv-strahlen schützende zusammensetzungen
NO20075312L (no) N-(N-sulfonylaminometyl)cyklopropankarboksamidderivater nyttige ved smertebehandling
NO20072409L (no) Substituerte n-sulfonylaminobenzyl-2-fenoksy acetamid-forbindelser
HRP20070286T3 (en) Substituted diketopiperazines and their use as oxytocyn antagonists
ATE556058T1 (de) 1-(2h)-isochinolonderivat
ECSP045369A (es) Derivados de n-[fenil(piperidin-2-il)metil]benzamida, su preparacion y su aplicacion en terapeutica
BR0211427A (pt) Compostos, processo para preparar os mesmos, composição adequada para combater fungos danosos, uso de compostos, e, processo para combater fungos danosos
BRPI0606845A2 (pt) derivados de (1,5-difenil-1h-pirazol-3-il)oxadiazol, o respectivo preparo e a respectiva aplicação em terapêutica
ATE175661T1 (de) Benzamid-derivate als vasopressin-antagonisten
BR0316609A (pt) Sinomenina e compostos de sinomenina, sìntese e uso
ECSP077215A (es) Derivados de n-(1h-indolil)-1h-indol-2-carboxamidas, su preparación y su aplicación en terapéutica
AR074817A1 (es) Dihidropiridona-amidas como moduladores de p2x7
AR049401A1 (es) Aza-biciclononanos
BRPI0411762A (pt) derivados de difenilpiridina, seu preparo e sua aplicação em terapêutica
EP1634874A4 (en) imidazolidine
BR0311410A (pt) Composto de piperidina
BRPI0813809A2 (pt) derivados de 7-alquinil -1,8-naftiridonas, sua preparação e sua aplicação em terapêutica.
NO20001781L (no) 3-amino-3-arylpropan-1-og lignende-derivater, deres fremstilling og anvendelse
MY140325A (en) Indanyl-piperazine derivatives, process for their preparation and pharmaceutical compositions containing them
EP1500648A4 (en) NEW PIPERIDINE DERIVATIVES
NO20060277L (no) Anvendelse av bisyklo [2.2.1] heptanderivater til fremstilling av nevrobeskyttende farmasoytiske sammensetninger

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements